The immune microenvironment in hormone receptor-positive breast cancer before and after preoperative chemotherapy.

CONCLUSIONS: The immune microenvironment of HR+/HER2-tumors differs according to tumor biology. This cohort of paired pre-/post-chemotherapy samples suggests a critical role for immunosuppressive macrophage expansion in residual disease. The role of macrophages in chemo-resistance should be explored and further evaluation of macrophage-targeting therapy is warranted. PMID: 31061067 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research

Related Links:

In this study, we evaluated the therapeutic benefit of combining the TAB004 antibody with Liposomal-MSA-IL-2 in immune competent and human MUC1 transgenic (MUC1.Tg) mouse models of PDA and investigated the associated immune responses. Treatment with TAB004 + Lip-MSA-IL-2 resulted in significantly improved survival and slower tumor growth compared to controls in MUC1.Tg mice bearing an orthotopic PDA.MUC1 tumor. Similarly, in the spontaneous model of PDA that expresses human MUC1, the combination treatment stalled the progression of pancreatic intraepithelial pre-neoplastic (PanIN) lesion to adenocarcinoma. Treatment with t...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
In conclusion, our findings support CTP as the optimum neoadjuvant regimen for HER2-positive breast cancer, with the best pCR and acceptable toxicity compared with CT. MP provides a therapeutic option for patients with poor performance status. PMID: 31015833 [PubMed]
Source: Journal of Oncology - Category: Cancer & Oncology Tags: J Oncol Source Type: research
, Trocóniz IF, Santisteban M Abstract AIM: Immunotherapy is a rising alternative to traditional treatment in breast cancer (BC) patients in order to transform cold into hot immune enriched tumours and improve responses and outcome. A computational modelling approach was applied to quantify modulation effects of immunotherapy and chemotherapy response on tumour shrinkage and progression-free survival (PFS) in naïve BC patients. METHODS: Eighty-three Her2-negative BC patients were recruited for neoadjuvant chemotherapy with or without immunotherapy based on dendritic cell vaccination. Sequential tum...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Br J Clin Pharmacol Source Type: research
By BISHAL GYAWALI MD, PhD Hey, I’m back! Well, you might not have noticed that my blogs were missing for the last three months but anyways, its good to be back. I was having a little time off blogs and social media as I was transitioning in my career but now I am back. Sometimes, it is very difficult to manage time for things that you must do versus things you enjoy doing, especially when these two don’t intersect. For me, these last few months the things I had to do were all bureaucratic while I couldn’t find the time for things I enjoy doing like writing these blogs. But now that we are back,...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Medical Practice Physicians Bishal Gyawali Cancer drugs Clinical Trials Oncology Prostate Cancer RCTs Source Type: blogs
SummaryWhile immunotherapy (IOT) with monoclonal antibodies has long been present in HER2-positive breast cancer, the development of modern IOT concepts such as PD-1/PD-L1 targeting immune checkpoint inhibitors has been slow compared with other malignancies such a  melanoma or lung cancer. Recent clinical trials of IOT have focused on triple-negative breast cancer (TNBC) as no specific treatment options beyond chemotherapy have been available in this subtype; in addition, TNBC apparently harbours the largest immunogenic potential. Meanwhile, initial results from the phase III IMpassion130 trial have been presente...
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research
AbstractPurpose of ReviewThe purpose of the review is to summarize the data regarding PD-L1 expression in breast cancer and the results of first clinical trials with PD-1 or PD-L1 inhibitors in patients with metastatic breast cancer.Recent FindingsPD-L1 expression is heterogeneous across primary breast cancers, and is generally associated with the presence of tumor-infiltrating lymphocytes and the presence of poor-prognosis features such as high grade, and aggressive molecular subtypes (triple-negative (TN), basal, HER2-enriched). Early phase clinical trials using PD-1 or PD-L1 inhibitors alone or in combination have shown...
Source: Current Oncology Reports - Category: Cancer & Oncology Source Type: research
Conclusion: TM with IBR after NACT is feasible surgical treatment option in breast cancer patients.canres;77/4_Supplement/P2-04-26/table1T1Clinicopathologic characteristicsVariablesControl group (n=85)Study group (n=31)p-valueAge, years (matching variables)0.890≤3515 (17.7)9 (29.0)36-5061 (71.8)21 (67.7)51≥9 (10.6)1 (3.2)BMI, m2/kg0.13025≤62 (72.9)28 (90.3)26-3018 (21.2)2 (6.5)30>5 (5.9)1 (3.2)Histology0.326Ductal carcinoma in situ2 (2.4)3 (9.7)Invasive ductal carcinoma74 (87.1)28 (90.3)Invasive lobular carcinoma2 (2.4)0 (0)Others7 (8.2)0 (0)Multiplicity0.063yes19 (22.6)12 (40.0)no65 (77.4)18 (60.0)Lymphovascul...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
Tumor infiltrating lymphocytes (TILs) play a critical role in regulating the immunomodulatory properties of triple negative breast cancer (TNBC). However, the specific adaptations that TNBC tumors undergo when challenged by lymphocyte infiltration remain unclear. In order to address this gap in knowledge, we conducted an immuno-phenotype comparison using mRNA sequencing between the TNBC cell line MDA-MB-231 and the luminal breast cancer cell line MCF7 after both were co-cultured with activated human T-cells. Although the cytokine-induced immune signature of the two cell lines were similar, MDA-MD-231 cells were able to tra...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
Triple negative breast cancer (TNBC), defined as tumors lacking expression of the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), are especially difficult to treat effectively. While ER+ and HER2+ breast cancer subtypes can be treated with Tamoxifen and Herceptin, respectively, there are no targeted therapies for TNBC patients. Furthermore, while only 20-30% of TNBC patients respond to chemotherapy in the neoadjuvant setting, overall outcome remains poor for non-responding patients. However, mounting evidence suggests that immune-checkpoint inhibitor immunotherapies m...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
Conclusion: Pathological complete responses were higher in BC patients treated with neoadjuvant chemotherapy plus active immunotherapy. The addition of autologous dendritic cell vaccines to NAC increases significantly stromal TILs in breast cancer patients.Citation Format: Ciruelos EM, Montaño Á, Rodríguez CA, González-Flores E, Lluch A, Garrigós L, Quiroga V, Antón A, Malón D, Chacón JI, Velasco M, Gonzalez-Cortijo L, Jolis L, Pascual T, Amigo Y, Casas M, Cámara MC, Carrasco E, Casas A. Phase III trial to evaluate patient´s preference for subcutaneous ve...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
More News: Biology | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Genetics | HER2 | Hormones | Immunotherapy | Nanotechnology | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy